AstraZeneca Is a Cancer Leader. Obesity Could Be a Bonus.
Wall Street Journal
The Anglo-Swedish drugmaker remains one of the best bets in Big Pharma, and potential success in obesity isn’t priced in to the stock.
https://www.wsj.com/articles/astrazeneca-is-a-cancer-leader-obesity-could-be-a-bonus-42bf0392